Biotech News

argenx to Present at Upcoming Investor Conferences

Argenx (ARGX)ArgenxConference / presentation

May 27, 2026

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in June:

William Blair 46th Annual Growth Stock Conference. Presentation on Wednesday, June 3, 2026 at 12:40 p.m. CT in Chicago, IL.

Goldman Sachs 47th Annual Global Healthcare Conference . Fireside chat on Tuesday, June 9, 2026 at 4:00 p.m. ET in Miami, FL.

A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors . A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn , Instagram , Facebook , and YouTube .

Contacts

Media:

Ben Petok bpetok@argenx.com

Investors:

Alexandra Roy aroy@argenx.com

Related news

EXELExelixis2026-05-27 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

KURAKura Oncology2026-07-14 11:02 EST

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

CLDXCelldex Therapeutics2026-06-10 20:01 EST

Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress

TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST

Teva to Present at the Goldman Sachs Global Healthcare Conference

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

LYELLyell Immunopharma2026-06-25 12:00 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

COGTCogent Biosciences2026-06-12 12:01 EST

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

LYELLyell Immunopharma2026-06-01 12:00 EST

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

GERNGeron2026-06-01 12:00 EST

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Argenx

Global Immunology Company Argenx develops therapies for severe autoimmune diseases. Its core commercial asset, VYVGART/efgartigimod, targets FcRn to reduce circulating IgG autoantibodies and has established a commercial base in generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and selected regional...

Recent company news

Stock data

Close
875.30 USD
Market cap
49.89B USD
Exchange
NASDAQ
Sector
Antibody Drugs
Location
United States